May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Trabecular Micro-Bypass Stent for Refractory Open-Angle Glaucoma Patients: 18-Month Results
Author Affiliations & Notes
  • F. De Feo
    DiNOG-Eye Clinic, University of Genova, Genoa, Italy
  • S. Gandolfi
    Eye Clinic, University of Parma, Parma, Italy
  • F. M. Honrubia Lopez
    Servicio de Oftalmología, Hospital Univrsitario Miguel Servet, Zaragoza, Spain
  • H. Hoh
    Eye Clinic, Universität Neubrandenburg, Neubrandenburg, Germany
  • J. Garcia Sanchez
    Eye Clinic, Hospital Clínico Universitario San Carlos, Madrid, Spain
  • C. E. Traverso
    DiNOG-Eye Clinic, University of Genova, Genoa, Italy
  • Footnotes
    Commercial Relationships  F. De Feo, None; S. Gandolfi, None; F.M. Honrubia Lopez, None; H. Hoh, None; J. Garcia Sanchez, None; C.E. Traverso, Glaukos, F.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4187. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. De Feo, S. Gandolfi, F. M. Honrubia Lopez, H. Hoh, J. Garcia Sanchez, C. E. Traverso; Trabecular Micro-Bypass Stent for Refractory Open-Angle Glaucoma Patients: 18-Month Results. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4187. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the efficacy of the iStent Trabecular Micro-Bypass Stent (Glaukos Corp.) in patients with open angle glaucoma, refractory to previously attempted medical and surgical therapies.

Methods: : Prospective, open-labeled, 24 month, multi-country evaluation of 45 patients with uncontrolled advanced primary open-angle glaucoma who underwent ab-interno stent implantation. The device reduces aqueous resistance by creating a long-lasting patent bypass between the anterior chamber and Schlemm’s canal. The stent is inserted through a 1.0 mm temporal clear corneal incision. Enrolled patients were required to have undergone previous conventional medical and surgical therapies that failed or were considered to have a poor prognosis for filtration surgery. Thirty patients completed 18 months; results are presented in this interim analysis. Primary end point was achievement of an IOP ≤21 mm Hg. Secondary end point was reduction in mean medication use.

Results: : Mean preoperative IOP was 28.4 (±6.39) mm Hg at baseline and 17.9 (±3.62) mm Hg at month 18 (P=0.0001). At baseline, the mean number of medications was 2.1 (±0.94); by month 18 the mean number of medications was 1.2 (±1.18). This was statistically significant (P<0.0001). One-third of patients completing the 18-month evaluation (10 eyes) achieved an IOP ≤ 21 mm Hg with no ocular hypotensive medications. Overall, 90% of eyes reached an IOP of ≤ 21 mm Hg. The most commonly reported adverse event was trabeculectomy (n=13).

Conclusions: : The iStent was safe and efficacious in difficult-to-treat patients who had failed on prior therapy and/or surgery or were considered poor candidates for filtering procedures. This ab-interno procedure resulted in statistically significant reductions in mean IOP and reduced reliance on medications.

Clinical Trial: : NCT00326040

Keywords: intraocular pressure • outflow: trabecular meshwork 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.